MannKind Corporation (MNKD): Price and Financial Metrics

MannKind Corporation (MNKD): $4.06

0.04 (-0.98%)

POWR Rating

Component Grades








Add MNKD to Watchlist
Sign Up

Industry: Biotech




#45 of 359

in industry

MNKD Price/Volume Stats

Current price $4.06 52-week high $5.75
Prev. close $4.10 52-week low $2.91
Day low $4.02 Volume 504,842
Day high $4.12 Avg. volume 3,013,560
50-day MA $4.58 Dividend yield N/A
200-day MA $4.54 Market Cap 1.09B

MNKD Stock Price Chart Interactive Chart >


  • MNKD scores best on the Growth dimension, with a Growth rank ahead of 96.65% of US stocks.
  • The strongest trend for MNKD is in Value, which has been heading up over the past 177 days.
  • MNKD ranks lowest in Stability; there it ranks in the 10th percentile.

MNKD Stock Summary

  • MANNKIND CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 6.05% of US listed stocks.
  • MNKD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.64% of US stocks.
  • As for revenue growth, note that MNKD's revenue has grown 140.99% over the past 12 months; that beats the revenue growth of 95.96% of US companies in our set.
  • Stocks that are quantitatively similar to MNKD, based on their financial statements, market capitalization, and price volatility, are VAPO, APPS, OTRK, BYND, and SONX.
  • MNKD's SEC filings can be seen here. And to visit MANNKIND CORP's official web site, go to

MNKD Valuation Summary

  • MNKD's price/sales ratio is 6.9; this is 263.16% higher than that of the median Healthcare stock.
  • MNKD's price/sales ratio has moved NA NA over the prior 233 months.

Below are key valuation metrics over time for MNKD.

Stock Date P/S P/B P/E EV/EBIT
MNKD 2023-09-22 6.9 -4.2 -23.0 -62.1
MNKD 2023-09-21 7.0 -4.2 -23.2 -62.7
MNKD 2023-09-20 7.0 -4.3 -23.5 -63.1
MNKD 2023-09-19 7.2 -4.4 -24.0 -64.2
MNKD 2023-09-18 7.4 -4.5 -24.6 -65.4
MNKD 2023-09-15 7.4 -4.5 -24.6 -65.5

MNKD Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -102.86%.
  • Its 3 year cash and equivalents growth rate is now at 91.81%.
  • Its year over year price growth rate is now at -23.63%.
Over the past 33 months, MNKD's revenue has gone up $13,188,000.

The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 76.226 -90.65 -97.514
2022-06-30 65.612 -77.761 -87.508
2022-03-31 69.998 -67.226 -94.008
2021-12-31 75.442 -61.709 -80.926
2021-09-30 81.37 -49.127 -79.276
2021-06-30 74.511 -47.403 -86.105

MNKD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNKD has a Quality Grade of C, ranking ahead of 42.97% of graded US stocks.
  • MNKD's asset turnover comes in at 0.384 -- ranking 124th of 680 Pharmaceutical Products stocks.
  • VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.

The table below shows MNKD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.384 0.611 -0.321
2021-03-31 0.424 0.627 -0.330
2020-12-31 0.673 0.622 -0.564
2020-09-30 0.673 0.595 -0.391
2020-06-30 0.666 0.529 -0.297
2020-03-31 0.705 0.516 -0.324

MNKD Price Target

For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.33 (Strong Buy)

MannKind Corporation (MNKD) Company Bio

MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.

MNKD Latest News Stream

Event/Time News Detail
Loading, please wait...

MNKD Latest Social Stream

Loading social stream, please wait...

View Full MNKD Social Stream

Latest MNKD News From Around the Web

Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.

7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth

Pharma stocks can be a great investment, particularly if they have solid performance, revenue growth and a positive outlook.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | September 7, 2023

MannKind Corporation Announces Participation at Upcoming Conferences

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. H.C. Wainwright 25th Annual Global Investment Conference – Monday, September 11, 2023 at 8:30 am (ET) Morgan Stanley 21st Annual Global Healthcare Conferen

Yahoo | September 5, 2023

12 Best High Risk Penny Stocks to Buy Now

In this article, we will take a look at the 12 best high risk penny stocks to buy now. To see more such companies, go directly to 5 Best High Risk Penny Stocks to Buy Now. Investors are jubilant over Nvidia crushing analyst estimates in its latest quarterly report. Analysts are increasing their price targets […]

Yahoo | August 28, 2023

When Will MannKind Corporation (NASDAQ:MNKD) Breakeven?

We feel now is a pretty good time to analyse MannKind Corporation's ( NASDAQ:MNKD ) business as it appears the company...

Yahoo | August 22, 2023

3 Biotech Stocks to Sell in August Before They Crash and Burn

These biotech stocks are set to crash and burn, so it's probably a good idea for investors to sell in August, before it's too late.

Alex Sirois on InvestorPlace | August 14, 2023

Read More 'MNKD' Stories Here

MNKD Price Returns

1-mo -13.06%
3-mo -0.25%
6-mo -0.98%
1-year 27.67%
3-year 110.36%
5-year 121.86%
YTD -22.96%
2022 20.59%
2021 39.62%
2020 142.64%
2019 21.70%
2018 -54.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!